Superiority:

134678-17-4 in China Lamivudine

LONZEAL Pharmaceuticals was founded in 2006 and has become a leading manufacturing company covering finished formulation, active pharmaceutical ingredients and advanced intermediates, where ICH guidelines have been strictly applied in the whole chain of R&D, manufacturing process and quality management.

LONZEAL is taking attentiveness and profession to build high quality products, and contributing to health and beautiful life for everyone in the world. The products and manufacturing site of Lonzeal have been approved and inspected by stringent drug authorities such as USFDA, WHO, China NMPA, Brazil ANVISIA and India DCGI, based on which, we have been supplying to esteemed customers globally in the past 15 years with regulatory compliance and good quality.

We have manufacturing site located in Hebei National Biomedical Industrial Zone, FPPs and APIs R&D Center of in Shijiazhuang Hi-tech Development Park, and the commercial office in Beijing, China.

Our current main products cover anti-virus, anti-depression and anti-neuropathic pain areas. Lonzeal has become one of the key manufacturers in the global supply of anti-HIV drugs and is providing support to the treatment need of over 4 Million patients each year worldwide.

Lamivudine is a nucleoside analogue, an antiviral drug, that has a competitive inhibitory effect on the synthesis and elongation of viral DNA strands. Its English name is Lamivudine, chemical name is 2'3' -dideoxy-3 '-thiocytosine (2' 3'deoxy-3'-thiocytidine), also known as 3-TC.